TIDMHIK

RNS Number : 1352R

Hikma Pharmaceuticals Plc

06 December 2016

Hikma Pharmaceuticals PLC

Voting Rights and Capital

LONDON, 6 December 2016, Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that its capital consists of 239,954,532 ordinary shares with voting rights. There are nil shares held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FCA's Disclosure and Transparency Rules.

- ENDS -

Enquiries

 
 Hikma Pharmaceuticals PLC 
 Peter Speirs 
  Company Secretary           +44 20 7399 2760

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVREAPAKEEDKFFF

(END) Dow Jones Newswires

December 06, 2016 13:04 ET (18:04 GMT)

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Hikma Pharmaceuticals Charts.